drugset / Trial / NCT00126880
AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study will measure how safe and effective AVX754 (a new drug for the treatment of HIV) is in treating HIV-1 infected people who have failed treatment with lamivudine.
Timeline
- Start
- 2005-07
- Primary completion
- 2008-01
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lamivudine | Other / unclassified | 150 mg | — |
| Subject | apricitabine | Small molecule | 600 mg | — |
| Subject | apricitabine | Small molecule | 800 mg | — |